Vinante F, Vassanelli A, Zanotti R, Nadali G, Krampera M, Vincenzi C, Morosato L, Chilosi M, Pizzolo G
Department of Hematology, Verona University School of Medicine, Italy.
Int J Clin Lab Res. 1995;25(4):189-94. doi: 10.1007/BF02592696.
One hundred and twenty-four sera from patients with various leukemic B-cell chronic lymphoproliferative diseases were investigated at diagnosis by ELISA for their soluble CD23 content. Immunophenotyping was carried out in all patients, and in a selected subset the mean number of membrane-bound CD23 molecules per cell was also investigated. Seventy-three patients had typical B chronic lymphocytic leukemia, 41 leukemic B-cell disorders with atypical morphological and/or immunophenotypic features, 5 had low-grade follicular cell lymphoma in the leukemic phase, and 5 had splenic lymphoma with villous lymphocytes. Soluble CD23 levels were significantly higher than in normal sera (mean +/- SD: typical B chronic lymphocytic leukemia 3,650 +/- 4,654 U/ml, atypical B chronic lymphocytic leukemia 3,440 +/- 4,671 U/ml, follicular cell lymphoma 3,200 +/- 1,511 U/ml, splenic lymphoma with villous lymphocytes 8,236 +/- 7,294 U/ml, controls 137 +/- 128 U/ml; P < 0.001). More advanced Rai's stages were related to higher soluble CD23 levels (P < 0.01), both in typical and atypical B chronic lymphocytic leukemias, the highest levels and the best correlation with the absolute number of circulating CD19+ cells (r = 0.50) being observed in the typical form. The number of membrane-bound CD23 molecules per cell was significantly higher in typical than in atypical B chronic lymphocytic leukemias (mean number 156,727 +/- 94,668 vs. 12,010 +/- 10,643, P < 0.001). Our data suggest that soluble CD23 levels correlate with the clinical and biological features of leukemic B-cell lymphoproliferative disorders.
采用酶联免疫吸附测定法（ELISA）对124例不同类型B细胞慢性淋巴细胞增殖性疾病患者在诊断时的血清可溶性CD23含量进行了检测。对所有患者进行了免疫表型分析，并在选定的亚组中研究了每个细胞上膜结合CD23分子的平均数。73例患者患有典型的B细胞慢性淋巴细胞白血病，41例为具有非典型形态学和/或免疫表型特征的白血病性B细胞疾病，5例为白血病期的低级别滤泡细胞淋巴瘤，5例为伴有绒毛状淋巴细胞的脾淋巴瘤。可溶性CD23水平显著高于正常血清（均值±标准差：典型B细胞慢性淋巴细胞白血病为3650±4654 U/ml，非典型B细胞慢性淋巴细胞白血病为3440±4671 U/ml，滤泡细胞淋巴瘤为3200±1511 U/ml，伴有绒毛状淋巴细胞的脾淋巴瘤为8236±7294 U/ml，对照组为137±128 U/ml；P<0.001）。在典型和非典型B细胞慢性淋巴细胞白血病中，Rai分期越晚，可溶性CD23水平越高（P<0.01），在典型类型中观察到最高水平且与循环CD19+细胞绝对数的相关性最佳（r=0.50）。典型B细胞慢性淋巴细胞白血病中每个细胞上膜结合CD23分子的数量显著高于非典型B细胞慢性淋巴细胞白血病（平均数分别为156727±94668和12010±10643，P<0.001）。我们的数据表明，可溶性CD23水平与白血病性B细胞淋巴增殖性疾病的临床和生物学特征相关。
